TFRC and ACTB as the best reference genes to quantify Urokinase Plasminogen Activator in breast cancer

详细信息    查看全文

• 作者：Keivan Majidzadeh-A (1) r> Rezvan Esmaeili (1) r> Nasrin Abdoli (1) r>
• 刊名：BMC Research Notes
• 出版年：2011
• 出版时间：December 2011
• 年：2011
• 卷：4
• 期：1
• 全文大小：360KB
• 参考文献：1. Steven SC, Donatus U, b E: rong class="a-plus-plus">Breast cancer as a global health concern.rong> / Cancer Epidemiology 2009, rong class="a-plus-plus">33:rong>315鈥?18. rnal" href="http://dx.doi.org/10.1016/j.canep.2009.10.003">CrossRef r> 2. Mousavi SM, Montazeri A, Mohagheghi MA, Jarrahi AM, Harirchi I, Najafi M, Ebrahimi M: rong class="a-plus-plus">Breast cancer in Iran: an epidemiological review.rong> / Breast J 2007, rong class="a-plus-plus">13:rong>383鈥?91. rnal" href="http://dx.doi.org/10.1111/j.1524-4741.2007.00446.x">CrossRef r> 3. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, / et al.: rong class="a-plus-plus">A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer.rong> / N Engl J Med 2004, rong class="a-plus-plus">351:rong>2817鈥?826. rnal" href="http://dx.doi.org/10.1056/NEJMoa041588">CrossRef r> 4. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC Jr: rong class="a-plus-plus">American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer.rong> / J Clin Oncol 2007, rong class="a-plus-plus">25:rong>5287鈥?292. rnal" href="http://dx.doi.org/10.1200/JCO.2007.14.2364">CrossRef r> 5. Look M, van Putten W, Duffy M, Harbeck N, Christensen IJ, Thomssen C, Kates R, Spyratos F, Fern枚 M: rong class="a-plus-plus">Pooled Analysis of Prognostic Impact of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in 8377 Breast Cancer Patients.rong> / Thromb Haemost 2003, rong class="a-plus-plus">90:rong>538鈥?48. r> 6. Foekens JA, Schmitt M, van Putten WL, Peters HA, Bontenbal M, J盲nicke F, Klijn JGM: rong class="a-plus-plus">Prognostic Value of Urokinase-type Plasminogen Activator in 671 Primary Breast Cancer Patients.rong> / Cancer Research 1992, rong class="a-plus-plus">52:rong>6101鈥?105. r> 7. Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, Br眉nner N, J盲nicke F, Gelder MEM-v, Henzen-Logmans SC, / et al.: rong class="a-plus-plus">The Urokinase System of Plasminogen Activation and Prognosis in 2780 Breast Cancer Patients.rong> / Cancer Research 2000, rong class="a-plus-plus">60:rong>636鈥?43. r> 8. Benraad TJ, Geurts-Moespot J, Gr酶ndahl-Hansen J, Schmitt M, Heuvel JJ, de Witte JH, Foekens J, Leake R, Br眉nner N, Sweep C: rong class="a-plus-plus">Immunoassays (ELISA) of Urokinase-type Masminogen Activator (u.PA): Report of an EORTCIBIOMED-1 Workshop.rong> / Eur J Cancer 1996, rong class="a-plus-plus">32A:rong>1371鈥?381. rnal" href="http://dx.doi.org/10.1016/0959-8049(96)00118-9">CrossRef r> 9. Schnitt SJ: rong class="a-plus-plus">Breast Cancer in the 21st Century: Neu Opportunities and Neu Challenges.rong> / Mod Pathol 2001, rong class="a-plus-plus">14:rong>213鈥?18. rnal" href="http://dx.doi.org/10.1038/modpathol.3880288">CrossRef r> 10. Yaziji H, Gown AM: rong class="a-plus-plus">Testing for HER-2/neu in Breast Cancer: Is Fluorescence In Situ Hybridization Superior in Predicting Outcome?rong> / Adv Anat Pathol 2002, rong class="a-plus-plus">9:rong>338鈥?44. rnal" href="http://dx.doi.org/10.1097/00125480-200211000-00002">CrossRef r> 11. Valasek MA, Repa JJ: rong class="a-plus-plus">The power of real-time PCR.rong> / Adv Physiol Educ 2005, rong class="a-plus-plus">29:rong>151鈥?59. rnal" href="http://dx.doi.org/10.1152/advan.00019.2005">CrossRef r> 12. Walker NJ: rong class="a-plus-plus">Tech.Sight. A technique whose time has come.rong> / Science 2002, rong class="a-plus-plus">296:rong>557鈥?59. rnal" href="http://dx.doi.org/10.1126/science.296.5567.557">CrossRef r> 13. de la Grange P, Dutertre M, Martin N, Auboeuf D: rong class="a-plus-plus">FAST DB: a website resource for the study of the expression regulation of human gene products.rong> / Nucleic Acids Res 2005, rong class="a-plus-plus">33:rong>4276鈥?284. rnal" href="http://dx.doi.org/10.1093/nar/gki738">CrossRef r> 14. Eisenberg E, Levanon EY: rong class="a-plus-plus">Human housekeeping genes are compact.rong> / Trends Genet 2003, rong class="a-plus-plus">19:rong>362鈥?65. rnal" href="http://dx.doi.org/10.1016/S0168-9525(03)00140-9">CrossRef r> 15. Hsiao LL, Dangond F, Yoshida T, Hong R, Jensen RV, Misra J, Dillon W, Lee KF, Clark KE, Haverty P, / et al.: rong class="a-plus-plus">A compendium of gene expression in normal human tissues.rong> / Physiol Genomics 2001, rong class="a-plus-plus">7:rong>97鈥?04. r> 16. R茅villion F, Pawlowski V, Hornez L, Peyrat JP: rong class="a-plus-plus">Glyceraldehyde-3-phosphate dehydrogenase gene expression in human breast cancer.rong> / Eur J Cancer 2000, rong class="a-plus-plus">36:rong>1038鈥?042. rnal" href="http://dx.doi.org/10.1016/S0959-8049(00)00051-4">CrossRef r> 17. McNeill RE, Miller N, Kerin MJ: rong class="a-plus-plus">Evaluation and validation of candidate endogenous control genes for real-time quantitative PCR studies of breast cancer.rong> / BMC Mol Biol 2007, rong class="a-plus-plus">27:rong>107鈥?19. rnal" href="http://dx.doi.org/10.1186/1471-2199-8-107">CrossRef r> 18. de Kok JB, Roelofs RW, Giesendorf BA, Pennings JL, Waas ET, Feuth T, Swinkels DW, Span PN: rong class="a-plus-plus">Normalization of gene expression measurements in tumor tissues: comparison of 13 endogenous control genes.rong> / Lab Invest 2004, rong class="a-plus-plus">85:rong>154鈥?59. r> 19. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F: rong class="a-plus-plus">Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes.rong> / Genome Biol 2002, rong class="a-plus-plus">3:rong>RESEARCH0034. rnal" href="http://dx.doi.org/10.1186/gb-2002-3-7-research0034">CrossRef r> 20. Li YL, Ye F, Hu Y, Lu WG, Xie X: rong class="a-plus-plus">Identification of suitable reference genes for gene expression studies of human serous ovarian cancer by real-time polymerase chain reaction.rong> / Anal Biochem 2009, rong class="a-plus-plus">394:rong>110鈥?16. rnal" href="http://dx.doi.org/10.1016/j.ab.2009.07.022">CrossRef r> 21. Killeen S, Hennessey A, El Hassan Y, Waldron B: rong class="a-plus-plus">The urokinase plasminogen activator system in cancer: a putative therapeutic target?rong> / Drug News Perspect 2008, rong class="a-plus-plus">21:rong>107鈥?16. rnal" href="http://dx.doi.org/10.1358/dnp.2008.21.2.1188197">CrossRef r> 22. Andersen C, Jensen J, Orntoft T: rong class="a-plus-plus">Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets.rong> / Cancer Res 2004, rong class="a-plus-plus">64:rong>5245鈥?250. rnal" href="http://dx.doi.org/10.1158/0008-5472.CAN-04-0496">CrossRef r> 23. Castell贸 R, Estell茅s A, V谩zquez C, Falc贸 C, Espa帽a F, Almenar SM, Fuster C, Aznar J: rong class="a-plus-plus">Quantitative Real-Time Reverse Transcription-PCR Assay for Urokinase Plasminogen Activator, Plasminogen Activator Inhibitor Type 1, and Tissue Metalloproteinase Inhibitor Type 1 Gene Expressions in Primary Breast Cancer.rong> / Clin Chem 2002, rong class="a-plus-plus">48:rong>1288鈥?295. r> 24. Biermann J, Holzscheiter L, Kotzsch M, Luther T, Kiechle-Bahat M, Sweep F, Span P, Schmitt M, Magdolen V: rong class="a-plus-plus">Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.rong> / Int J Mol Med 2008, rong class="a-plus-plus">21:rong>251鈥?59. r> 25. Pierga JY, Bonneton C, Magdel茅nat H, Vincent-Salomon A, Nos C, Boudou E, Pouillart P, Thiery JP, Cremoux Pd: rong class="a-plus-plus">Real-time quantitative PCR determination of urokinase-type plasminogen activator receptor (uPAR) expression of isolated micrometastatic cells from bone marrow of breast cancer patients.rong> / International Journal of Cancer 2005, rong class="a-plus-plus">114:rong>291鈥?98. rnal" href="http://dx.doi.org/10.1002/ijc.20698">CrossRef r> 26. Konigshoff M, Wilhelm J, Bohle RM, Pingoud A, Hahn M: rong class="a-plus-plus">HER-2/neu Gene Copy Number Quantified by Real-Time PCR: Comparison of Gene Amplification, Heterozygosity, and Immunohistochemical Status in Breast Cancer Tissue.rong> / Clin Chem 2003, rong class="a-plus-plus">49:rong>219鈥?29. rnal" href="http://dx.doi.org/10.1373/49.2.219">CrossRef r> 27. Schlemmer BO, Sorensen BS, Overgaard J, Olsen KE, Gjerdrum LM, Nexo E: rong class="a-plus-plus">Quantitative PCR - new diagnostic tool for quantifying specific mRNA and DNA molecules: HER2/neu DNA quantification with LightCycler real-time PCR in comparison with immunohistochemistry and fluorescence in situ hybridization.rong> / Scandinavian Journal of Clinical & Laboratory Investigation 2004, rong class="a-plus-plus">64:rong>511鈥?22. rnal" href="http://dx.doi.org/10.1080/00365510410002922">CrossRef r> 28. Capizzi E, Gruppioni E, Grigioni A, Gabusi E, Grassigli A, Grigioni W, Fiorentino M: rong class="a-plus-plus">Real time RT-PCR approach for the evaluation of ERBB2 overexpression in breast cancer archival samples: a comparative study with FISH, SISH, and immunohistochemistry.rong> / Diagn Mol Pathol 2008, rong class="a-plus-plus">17:rong>220鈥?26. rnal" href="http://dx.doi.org/10.1097/PDM.0b013e318161f993">CrossRef r> 29. Nistor A, Watson P, Pettigrew N, Tabiti K, Dawson A, Myal Y: rong class="a-plus-plus">Real-time PCR complements immunohistochemistry in the determination of HER-2/neu status in breast cancer.rong> / BMC Clinical Pathology 2006, rong class="a-plus-plus">6:rong>2. rnal" href="http://dx.doi.org/10.1186/1472-6890-6-2">CrossRef r> 30. Becette V, Vignaud S, R茅gnier C, Labroqu茅re M, Fourme E, Menet E, Bi猫che I, Spyratos F: rong class="a-plus-plus">Gene transcript assay by real-time RT-PCR in epithelial breast cancer cells selected by laser microdissection.rong> / t J Biol Markers 2004, rong class="a-plus-plus">19:rong>100鈥?08. r> 31. de Cremoux P, Tran-Perennou C, Brockdorff B, Boudou E, Brunner N, Magdelenat H, Lykkesfeldt A: rong class="a-plus-plus">Validation of real-time RT-PCR for analysis of human breast cancer cell lines resistant or sensitive to treatment with antiestrogens.rong> / Endocr Relat Cancer 2003, rong class="a-plus-plus">10:rong>409鈥?18. rnal" href="http://dx.doi.org/10.1677/erc.0.0100409">CrossRef r> 32. Larionov A, Dixon J, Krause A, Evans D, Miller W: rong class="a-plus-plus">Validation of reference genes for relative real time PCR to study hormone-dependent gene expression in breast cancer biopsies.rong> / Breast Cancer Res Treat 2005., rong class="a-plus-plus">94:rong> r> 33. Drury S, Anderson H, Dowsett M: rong class="a-plus-plus">Selection of REFERENCE Genes for Normalization of qRT-PCR Data Derived From FFPE Breast Tumors.rong> / Diagnostic Molecular Pathology 2009, rong class="a-plus-plus">18:rong>103鈥?07. rnal" href="http://dx.doi.org/10.1097/PDM.0b013e31817c1ae2">CrossRef r> 34. Morse DL, Carroll D, Weberg L, Borgstrom MC, Ranger-Moore J, Gillies RJ: rong class="a-plus-plus">Determining suitable internal standards for mRNA quantification of increasing cancer progression in human breast cells by real-time reverse transcriptase polymerase chain reaction.rong> / Analytical Biochemistry 2005, rong class="a-plus-plus">342:rong>69鈥?7. rnal" href="http://dx.doi.org/10.1016/j.ab.2005.03.034">CrossRef r> 35. Gur-Dedeoglu B, Konu O, Bozkurt B, Ergul G, Seckin S, Yulug I: rong class="a-plus-plus">Identification of endogenous reference genes for qRT-PCR analysis in normal matched breast tumor tissues.rong> / Oncol Res 2009, rong class="a-plus-plus">17:rong>353鈥?65. rnal" href="http://dx.doi.org/10.3727/096504009788428460">CrossRef r> 36. Lyng M, Laenkholm A, Pallisgaard N, Ditzel H: rong class="a-plus-plus">Identification of genes for normalization of real-time RT-PCR data in breast carcinomas.rong> / BMC Cancer :20 2008, rong class="a-plus-plus">Jan 22:rong>20. rnal" href="http://dx.doi.org/10.1186/1471-2407-8-20">CrossRef r> 37. Waxman S, Wurmbach E: rong class="a-plus-plus">De-regulation of common housekeeping genes in hepatocellular carcinoma.rong> / BMC Genomics 2007, rong class="a-plus-plus">18:rong>243. rnal" href="http://dx.doi.org/10.1186/1471-2164-8-243">CrossRef r> 38. Khimani A, Mhashilkar A, Mikulskis A, O'Malley M, Liao J, Golenko E, Mayer P, Chada S, Killian J, Lott S: rong class="a-plus-plus">Housekeeping genes in cancer: normalization of array data.rong> / Biotechniques 2005, rong class="a-plus-plus">38:rong>739鈥?45. rnal" href="http://dx.doi.org/10.2144/05385ST04">CrossRef r>
• 作者单位：Keivan Majidzadeh-A (1) r> Rezvan Esmaeili (1) r> Nasrin Abdoli (1) r>r>1. Iranian Center for Breast Cancer (ICBC); Academic Center for Education, Culture and Research (ACECR), No 45, Nazari St, Aboureihan St, Enghelab Ave, Tehran, Iran r>

文摘

Background Biomedical researchers have long looked for ways to diagnose and treat cancer patients at the early stages through biomarkers. Although conventional techniques are routinely applied in the detection of biomarkers, attitudes towards using Real-Time PCR techniques in detection of many biomarkers are increasing. Normalization of quantitative Real-Time PCR is necessary to validate non-biological alteration occurring during the steps of RNA quantification. Selection of variably expressed housekeeping genes (HKs) will affect the validity of the data. The aim of the present study was to identify uniformly expressed housekeeping genes in order to use in the breast cancer gene expression studies. Urokinase Plasminogen Activator was used as a gene of interest. Findings The expression of six HKs (TFRC, GUSB, GAPDH, ACTB, HPRT1 and RPLP0) was investigated using geNorm and NormFinder softwares in forty breast tumor, four normal and eight adjacent tissues. RPLP0 and GAPDH revealed maximum M value, while TFRC demonstrated lowest M value. Conclusions In the present study the most and the least stable genes were TFRC and RPLP0 respectively. TFRC and ACTB were verified as the best combination of two genes for breast cancer quantification. The result of this study shows that in each gene expression analysis HKs selection should be done based on experiment conditions.